---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-25-000063"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:57:33.900934+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting

## Summary
- Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.
- Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.
- Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes.

## SEC filing metadata
- accession: 0001636282-25-000063
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/0001636282-25-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/syre-20250529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-25-000063
- JSON: https://secwatch.observer/filing/0001636282-25-000063.json
- Plain text: https://secwatch.observer/filing/0001636282-25-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.